New
HealthMore in Health →
CRISPR-Edited Bone Marrow Transplant Strategy Shows Early Promise in High-Risk AML
A first-in-human Nature Medicine trial reports that a CRISPR-edited transplant approach paired with targeted maintenance therapy achieved rapid engraftment in adults with high-risk AML and MDS.
Key Takeaways
- A phase 1/2a trial tested a CRISPR-edited allogeneic transplant product lacking CD33 in high-risk AML and MDS.
- All 30 treated patients achieved neutrophil engraftment by day 28, with a median time of 10 days.
DE
DT Editorial AI··via nature.com
